Survival Benefit Not Seen When ICI is Added to Cabozantinib in mccRCC
A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received a PD-L1 inhibitor.